Worldwide CNS Market Analyzed in New Aruvian’s R’search Report Available at MarketPublishers.com
11 Sep 2012 • by Natalie Aster
LONDON – The global central nervous system (CNS) market is one of the largest and fastest growing categories in the pharmaceutical industry. Within the numerous subcategories of the CNS disorders market, antipsychotics were the largest CNS drug class. Patent expirations of major brands Seroquel and Zyprexa are likely to form the main resistors to segmental growth over the forecast period.
Imminent patent expiries for leading brands have resulted in companies investigating new indications and re-formulation strategies to extend patents and safeguard revenue streams. Companies have also begun to manufacture and market generic versions of their products.
New report “Analyzing the Global CNS Market” worked out by Aruvian’s R’search offers a comprehensive guide to the global CNS industry, providing a market overview, an analysis of the market by CNS drug classes, an industry segmentation and an analysis of the leading industry products along with their sales figures. Novel emerging drug classes for CNS disorder treatment are also reviewed. The study examines the overall competitive landscape as well as profiles the top market players taking an up-close look at their CNS R&D pipeline, strategy for future growth in the industry and SWOT analysis. Furthermore, the report is supplemented with future perspective of the global CNS market.
Basic CNS disorders analyzed are: attention-deficit hyperactivity disorder (ADHD), Alzheimer's disease, epilepsy, insomnia, major depressive disorder (MDD), migraine, Parkinson's disease, and Schizophrenia.
Top market players mentioned include: AstraZeneca, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, and Pfizer.
Analyzing the Global CNS Market
Published: September, 2012
Price: US$ 650,00
More new market research reports by the publisher can be found at Aruvian’s R’search page.